Program Slides Download (PDF)
The diagnosis and management of multiple sclerosis (MS) continue to evolve with the rapid emergence of new agents, new diagnostic criteria, and the identification of MRI measures and biomarkers capable of improving disease surveillance. Combined with the continued push for earlier diagnosis and initiation of disease-modifying drug therapy (DMD), MS diagnosis and management is becoming increasingly complex. Clinicians face more treatment choices, making the formulation of optimal DMD therapies increasingly difficult. In addition, patient concerns with DMD side effects, treatment preferences, drug costs, and other issues continue to negatively impact patient acceptance of and adherence to DMD treatments.
This program will review the latest research and clinical management information on DMD therapies, diagnostic MRI measures, and biomarkers, in order to provide neurologists and other MS specialists with the knowledge and skills needed to improve the management and outcomes of patients with MS.
Suhayl Dhib-Jalbut, MD
Professor and Chairman
Department of Neurology
Rutgers-Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ
Clyde E. Markowitz, MD
Chief, MS Section
Director, MS Center
Associate Professor of Neurology
Perelman School of Medicine
University of Pennsylvania
Aaron E. Miller, MD
Professor of Neurology
Medical Director, The Corinne Goldsmith Dickinson
Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY
This activity is intended for MS specialists, neurologists, and other health care professionals who manage patients with MS.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Employ newer MRI criteria to improve the early diagnosis of MS
- Select and initiate effective DMD therapies earlier in the course of MS
- Describe the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies in MS
- Develop patient-tailored therapies that optimize adherence, increase effectiveness, and improve individual patient outcomes
- Apply evidence from recent diagnostic and prognostic biomarker studies to improve the monitoring of disease activity and response to DMD therapy in MS
- Welcome and Introduction
- Incorporating Advances in Early Diagnosis and Assessment in MS
- Selecting DMD Therapies Throughout the Course of MS
- Risk Factors and Prognostic Studies in MS
- Panel Discussion and Q&A Session
- Practice Pearls and Concluding Remarks
Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Nurses – Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Physicians – The Potomac Center for Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category I credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, evaluation, please email firstname.lastname@example.org.
Nurses – This educational activity for 1.50 contact hours is provided by Global Education Group. For information about the nursing accreditation of this program, please contact Global at email@example.com or 303-395-1782.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME/CE-certificate will be emailed to participants upon submission of a completed evaluation form.
There are no fees associated with this program.
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.).
Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly PROVIDED By
This program is supported by an educational grant from:
By clicking the Registration Button below you are agreeing that you have read and understood the CME/CE Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.